 "Panacea Biotec surges 15% on launch of Prasugrel drug in US market")
Panacea Biotec surged 15% to Rs 276, also its 52-week high on the BSE, after the company announced the launch of Prasugrel tablets in US market.
The company said that its first-to-file Abbreviated. New Drug Application (ANDA) of Prasugrel 5mg and 10mg tablets have been approved by the United States Food & Drug Administration (U.S.FDA).
Under the provisions of Hatch-Waxman Act, the Company is entitled for 180-days of shared marketing exclusivity for Prasugrel HCL tablets with this final FDA approval,” Panacea Biotec said in a press release.
The company earlier got the tentative approval for this ANDA on May 24, 2017.
According to an official release, the product has been launched in the market by Apotex Corp., the largest Canadian-owned pharmaceutical company which is the exclusive sales and distribution partner for this product in the US.
Panacea Biotec said Prasugrel has annual sales of approximately USD 600 million in the US and is indicated for reduction of thrombotic cardiovascular (including stent thrombosis) events in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).
At 01:16 PM; the stock was up 14% at Rs 273 on the BSE, as compared to 0.25% rise in the S&P BSE Sensex. The trading volumes on the counter jumped nearly five-fold with a combined 1.04 million shares changed hands on the BSE and NSE so far.
The company said that its first-to-file Abbreviated. New Drug Application (ANDA) of Prasugrel 5mg and 10mg tablets have been approved by the United States Food & Drug Administration (U.S.FDA).
Under the provisions of Hatch-Waxman Act, the Company is entitled for 180-days of shared marketing exclusivity for Prasugrel HCL tablets with this final FDA approval,” Panacea Biotec said in a press release.
The company earlier got the tentative approval for this ANDA on May 24, 2017.
According to an official release, the product has been launched in the market by Apotex Corp., the largest Canadian-owned pharmaceutical company which is the exclusive sales and distribution partner for this product in the US.
Panacea Biotec said Prasugrel has annual sales of approximately USD 600 million in the US and is indicated for reduction of thrombotic cardiovascular (including stent thrombosis) events in people with acute coronary syndrome (ACS) who are to be managed with percutaneous coronary intervention (PCI).
At 01:16 PM; the stock was up 14% at Rs 273 on the BSE, as compared to 0.25% rise in the S&P BSE Sensex. The trading volumes on the counter jumped nearly five-fold with a combined 1.04 million shares changed hands on the BSE and NSE so far.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%